Business & Finance
Wilson Therapeutics reduces loss in 2017
22 February 2018 -

Biopharmaceutical company Wilson Therapeutics AB (STO:WTX) reported on Wednesday loss of SEK168.2m, or SEK 6.50 per diluted share, for the full year 2017, from 1 January 2017to 31 December 2017.

This was an improvement over loss of SEK115.2m, or SEK6.84 per diluted share, in 2016.

Net sales for the year amounted to nil, same as sales in 2016.

The company's board of directors proposes that no dividend be paid for 2017.

Wilson Therapeutics develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics' lead product, WTX101, is in Phase 3 development as a novel treatment for Wilson Disease.